Racial and Ethnic Disparities in Malignant Melanoma: A Literature Review
Main Article Content
Keywords
melanoma, racial and ethnic health disparities, melanoma disparities, barriers to healthcare access
Abstract
Melanoma is a tumor arising from uncontrolled proliferation of melanocytes, neural crest derived cells responsible for production of pigment in the basal layer of the epidermis. While the prevalence of melanoma is greatest in fair-skinned populations, racial and ethnic minority populations disproportionately experience lower rates of survival when diagnosed with melanoma. Recent studies indicate that, among minority populations, melanoma tends to present at a more advanced stage with more aggressive melanoma subtypes, increased and atypical distributions over the body, and increased tumor depths. Populations of color are also shown to carry unique mutations in BRCA genes that may predispose them to developing melanoma and account for increased mortality rates. Socioeconomic status has also been linked to melanoma disparities, where limited access to quality healthcare including skin exams, insurance, and education may result in decreased melanoma survival rates. The aim of this article is to review the relationship between melanoma and underserved communities as well as discuss the current explanations behind these observations.
References
2. Ward-Peterson M, Acuña JM, Alkhalifah MK, et al. Association between race/ethnicity and survival of melanoma patients in the united states over 3 decades: A secondary analysis of SEER data. Medicine (Baltimore). 2016; 95:e3315.
3. Heistein JB, Acharya U. Malignant Melanoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2021.
4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021; 71:209-249.
5. Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: From pathogenesis to therapy. International journal of oncology. 2018; 52:1071-1080.
6. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136:E359-E386.
7. Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of Melanoma. In: Ward WH, Farma JM (eds). Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU): 2017.
8. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Archives of internal medicine (1960). 2006; 166:1907-1914.
9. Mahendraraj K, Sidhu K, Lau CSM, McRoy GJ, Chamberlain RS, Smith FO. Malignant melanoma in african-americans: A population-based clinical outcomes study involving 1106 african-american patients from the surveillance, epidemiology, and end result (SEER) database (1988-2011). Medicine (Baltimore). 2017; 96:e6258.
10. Hu S, Parmet Y, Allen G, et al. Disparity in melanoma: A trend analysis of melanoma incidence and stage at diagnosis among whites, hispanics, and blacks in florida. Archives of dermatology (1960). 2009; 145:1369-1374.
11. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert review of anticancer therapy. 2010; 10:1811-1823.
12. Hsueh EC, Lucci A, Qi K, Morton DL. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer. 1999; 85:383-388.
13. Tas F, Erturk K. Acral lentiginous melanoma is associated with certain poor prognostic histopathological factors but may not be correlated with nodal involvement, recurrence, and a worse survival. Pathobiology (Basel). 2018; 85:227-231.
14. Alcarraz CE, Morante Z, Mas L, et al. Outcomes and prognostic factors for acral lentiginous melanoma in peruvian patients. Journal of clinical oncology. 2016; 34:e21061.
15. Gupta AK, Bharadwaj M, Mehrotra R. Skin cancer concerns in people of color: Risk factors and prevention. Asian Pacific journal of cancer prevention : APJCP. 2016; 17:5257-5264.
16. Gutiérrez-Castañeda LD, Nova JA, Tovar-Parra JD. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: A systemic review. Melanoma research. 2020; 30:62-70.
17. Venkitaraman AR. Cancer Susceptibility and the Functions of BRCA1 and BRCA2. Cell. 2002; 108:171-182.
18. Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. British journal of dermatology (1951). 2015; 172:1498-1506.
19. Breast Cancer Linkage Consortium, T. Cancer risks in BRCA2 mutation carriers. JNCI : Journal of the National Cancer Institute. 1999; 91:1310-1316.
20. Dębniak T, Scott RJ, Górski B, et al. Common variants of DNA repair genes and malignant melanoma. European journal of cancer (1990). 2007; 44:110-114.
21. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: Distribution and clinical implications. Current opinion in obstetrics & gynecology. 2010; 22:72-78.
22. Golan T, Kindler HL, Park JO, et al. Geographic and ethnic heterogeneity of germline BRCA1 or BRCA2 mutation prevalence among patients with metastatic pancreatic cancer screened for entry into the POLO trial. Journal of clinical oncology. 2020; 38:1442-1454.
23. Haffty BG, Silber A, Matloff E, Chung J, Lannin D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African american compared to white women. Journal of medical genetics. 2006; 43:133-137.
24. Qing G, Tomlinson G, Das S, Cummings S. Prevalence of BRCA1 and BRCA2 mutations among clinic-based african american families with breast cancer. 2000.
25. Tripathi R, Archibald LK, Mazmudar RS, et al. Racial differences in time to treatment for melanoma. Journal of the American Academy of Dermatology. 2020; 83:854-859.
26. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma. Cancer. 1998; 83:1664-1678.
27. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the united states. Journal of investigative dermatology. 2009; 129:1666-1674.
28. Artiga S, Hill L, Orgera K, Damico A. Health Coverage by Race and Ethnicity, 2010-2019
29. Kooistra L, Chiang K, Dawes S, Gittleman H, Barnholtz-Sloan J, Bordeaux J. Racial disparities and insurance status: An epidemiological analysis of ohio melanoma patients. Journal of the American Academy of Dermatology. 2018; 78:998-1000.
30. Resneck J, Pletcher MJ, Lozano N. Medicare, medicaid, and access to dermatologists: The effect of patient insurance on appointment access and wait times. Journal of the American Academy of Dermatology. 2004; 50:85-92.
31. Saraiya M, Hall HI, Thompson T, et al. Skin cancer screening among U.S. adults from 1992, 1998, and 2000 national health interview surveys. Preventive medicine. 2004; 39:308-314.
32. Huff LS, Chang CA, Thomas JF, et al. Defining an acceptable period of time from melanoma biopsy to excision. Dermatology Reports. 2012; 4:e2.
33. Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S. Melanoma risk perception and prevention behavior among african-americans: The minority melanoma paradox. Clinical, cosmetic and investigational dermatology. 2015; 8:423-429.
34. Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in african americans. Journal of the American Academy of Dermatology. 2004; 50:21-24.
35. Pipitone M, Robinson JK, Camara C, Chittineni B, Fisher SG. Skin cancer awareness in suburban employees: A hispanic perspective. Journal of the American Academy of Dermatology. 2002; 47:118-123.
36. Ezenwa E, Buster K. Health Disparities and Skin Cancer in People of Color. Practical Dermatology. 2019; 38-42.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.